Eli Lilly and Company

Esteban Dominguez-Manzanares

Ana Maria Castano Mansanet

William Joseph Hornback

Dennis Michael Zimmerman

Hamideh Zarrinmayeh

Ana Maria Escribano

Zhipei Wu

Eric George Tromiczak

Delu Jiang

Jian Eric Hong

Frederic Laurent Cordier

Pamela Ann Albaugh

Paul Leslie Ornstein

Kenneth Allen Savin

James Peter Beck

Thomas John Bleisch

Kevin Matthew Gardinier

Maria Carmen Fernandez

William David Miller

Michelle Lee Thompson

Alma Maria Jimenez-Aguado

Brian David Wakefield

Peter Michael Greenen

Larry Gene Huffman

The present invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof which is useful for the treatment of conditions associated with glutamate hypofunction, such as psychiatric and neurological disorders. 

AMPA receptor potentiators

The present invention relates to a melanin concentrating hormone antagonist compound of formula (I); wherein Ar, L, R, q, X, R, R, R, and Rare as defined, or a pharmaceutically acceptable salt, solvate, or enantiomer thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and related diseases.

MCH receptor antagonists

The present invention relates to AMPA receptor potentiators of Formula I: formulations comprising them, methods for their use, and intermediates useful for their preparation.

The present invention relates to thiophene and furan compounds and their pharmaceutically acceptable salts, and further relates to their use in treating schizophrenia, cognitive deficits associated with schizophrenia, Alzheimer's disease, dementia of the Alzheimer's type, mild cognitive impairment, or depression.

Thiophene and furan compounds

The present invention relates to pyrrole and pyrazole compounds of formula (I) and their pharmaceutically acceptable salts, and further relates to their use in treating schizophrenia, cognitive deficits associated with schizophrenia, Alzheimer's disease, dementia of the Alzheimer's type, mild cognitive impairment, or depression. The compounds act as potentiators on glutamate receptors, in particular AMPA and the GluR family.

Pyrrole and pyrazole derivatives as potentiators of glutamate receptors

The present invention provides novel compounds of Formula (I), or the pharmaceutically acceptable salts or prodrugs thereof, and methods for treating neurological disorders and neurodegenerative diseases, particularly pain and migraine.

Excitatory amino acid receptor antagonists

Growing community of inventors

Madrid, Spain

Esteban Dominguez-Manzanares